"uuid:ID","text","id","name","instanceType","description","label"
"5dde71e7-fba0-44dd-8584-483f4fdcc4ae","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective_1","OBJ1","Objective","Main objective",""
"e45ce5af-81c2-4d3a-a79e-663076afe5c9","To document the safety profile of the xanomeline TTS.","Objective_2","OBJ2","Objective","Safety",""
"f62d63c6-94a1-4793-be1a-3a54f7dec890","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective_3","OBJ3","Objective","Behaviour",""
"c5e527fb-03ea-4475-9bf7-365bc003a133","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective_4","OBJ4","Objective","",""
"1d37404e-e1a0-4ba7-b364-a6aba9790453","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective_5","OBJ5","Objective","",""
"a0470263-0353-408e-b531-2f6324c3e5b9","To assess the treatment response as a function of Apo E genotype.","Objective_6","OBJ6","Objective","",""
